Comparative Pharmacology
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus XACDURO COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus XACDURO COPACKAGED.
PIPERACILLIN AND TAZOBACTAM vs XACDURO (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
Sulbactam-durlobactam: Sulbactam is a beta-lactamase inhibitor and also binds to penicillin-binding proteins (PBPs) of Acinetobacter baumannii, inhibiting cell wall synthesis. Durlobactam is a beta-lactamase inhibitor that protects sulbactam from degradation by certain beta-lactamases, including class A, C, and D serine beta-lactamases.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours, or 4.5 g (piperacillin 4 g + tazobactam 0.5 g) IV every 8 hours for nosocomial pneumonia.
XACDURO (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) intravenously over 2 hours every 8 hours.
None Documented
None Documented
Piperacillin ~0.7–1.2 h, tazobactam ~0.7–1.5 h; prolonged in renal impairment (piperacillin up to 3.3 h, tazobactam up to 5.6 h in severe impairment).
Sulbactam: ~1 hour; durlobactam: ~2 hours. In patients with moderate to severe renal impairment, half-life may be prolonged up to 3-4 times, requiring dose adjustment.
Primarily renal: piperacillin ~68% unchanged, tazobactam ~80% unchanged; biliary excretion <10%; fecal <1%.
Renal excretion of unchanged drug: sulbactam ~80%, durlobactam ~90% within 24 hours. Biliary/fecal elimination: minimal (<1%).
Category C
Category C
Penicillin Antibiotic / Beta-Lactamase Inhibitor Combination
Cephalosporin/Beta-Lactamase Inhibitor Combination